Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome

NCT02257697 is registered in ClinicalTrials.gov with Asahi Kasei Therapeutics Corporation as lead sponsor.

NCT NCT02257697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02257697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome
Lead sponsor
Asahi Kasei Therapeutics Corporation
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2014
Completion date
November 30, 2018
Enrollment
239 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

nephrotic syndrome